Clinical Trial Update: Sintilimab Combined With Chemotherapy as Adjuvant Treatment for Phase III GC and GEJ [Phase 2]

View source ↗

Summary

Sintilimab plus chemotherapy is being evaluated as adjuvant therapy in a Phase 2 study for gastric adenocarcinoma and esophagogastric junction adenocarcinoma, a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophagogastric Junction Adenocarcinoma
• Gastric Adenocarcinoma

Drugs mentioned

• Sintilimab (sintilimab)

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: Gastric Adenocarcinoma, Esophagogastric Junction Adenocarcinoma | Phase 2 | Status: RECRUITING